Live Breaking News & Updates on Hether Its Vaccine Products Will Be Commercially Accepted And Profitable

VANCOUVER, BC, June 15, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine. BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used by BioVaxys' Lyon-based manufacturing partner, BioElpida ("BioElpida"), to validate the tumor collection protocol, cryopackaging, cryopreservation, and ....

United States , United Kingdom , British Columbia , David Berd , Davin Shinedling , Kenneth Kovan , Biovaxys Technology Corp , Jba Inc , Biovaxys Co , Biovaxys Or Company , Prnewswire Biovaxys Technology Corp , Deaconess Research Institute , Vaxys Technology , Hospices Civils De Lyon , Good Manufacturing Process , Biovaxy Lyon Based , Vaxys President , Chief Operating Officer Kenneth Kovan , Biovaxys Co Founder , Chief Medical Officer , British Columbia Registered , Frankfurt Bourse , Statements Regarding Forward Looking Information , June 15 , 022 Prnewswire Biovaxys Technology Corp Cse Biov Fra 5lb Otcqb Bvaxf Quot Or Company , Nnounced Today That Its Clinical Study Collaborator Hospices Civils De Lyon In France Quot Hcl Has Surgically Excised The First Ovarian Cancer Tumors From Patients To Be Used By Biovaxys For Process Development And Manufacturing Dry Runs Of Bvx 0918 ,